Т. Н. Толстых

402 total citations
14 papers, 346 citations indexed

About

Т. Н. Толстых is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Т. Н. Толстых has authored 14 papers receiving a total of 346 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Hematology and 4 papers in Molecular Biology. Recurrent topics in Т. Н. Толстых's work include COVID-19 and healthcare impacts (4 papers), Acute Myeloid Leukemia Research (3 papers) and Neutropenia and Cancer Infections (3 papers). Т. Н. Толстых is often cited by papers focused on COVID-19 and healthcare impacts (4 papers), Acute Myeloid Leukemia Research (3 papers) and Neutropenia and Cancer Infections (3 papers). Т. Н. Толстых collaborates with scholars based in Russia and United States. Т. Н. Толстых's co-authors include Pei‐Jer Chen, Juneyoung Lee, Jeffry B. Stock, С. В. Семочкин, А. М. Ковригина and Marina A. Orlova and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and The EMBO Journal.

In The Last Decade

Т. Н. Толстых

9 papers receiving 336 citations

Peers

Т. Н. Толстых
Allison M. Manuel United States
Gema Lordén United States
Chu‐Fang Chou United States
Changyong Hu Singapore
Jelmi uit de Bos Netherlands
Т. Н. Толстых
Citations per year, relative to Т. Н. Толстых Т. Н. Толстых (= 1×) peers Chiara Merigliano

Countries citing papers authored by Т. Н. Толстых

Since Specialization
Citations

This map shows the geographic impact of Т. Н. Толстых's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Т. Н. Толстых with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Т. Н. Толстых more than expected).

Fields of papers citing papers by Т. Н. Толстых

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Т. Н. Толстых. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Т. Н. Толстых. The network helps show where Т. Н. Толстых may publish in the future.

Co-authorship network of co-authors of Т. Н. Толстых

This figure shows the co-authorship network connecting the top 25 collaborators of Т. Н. Толстых. A scholar is included among the top collaborators of Т. Н. Толстых based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Т. Н. Толстых. Т. Н. Толстых is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
2.
Толстых, Т. Н., et al.. (2024). Nivolumab-containing therapy in patients with newly diagnosed classical Hodgkin lymphoma: own clinical observations and literature review. SHILAP Revista de lepidopterología. 19(4). 52–72.
3.
Толстых, Т. Н., et al.. (2024). Treatment features of adult patients with acute myeloid leukemia during the COVID-19 pandemic. SHILAP Revista de lepidopterología. 18(4). 40–44.
4.
Толстых, Т. Н., et al.. (2024). COVID-19 in patients with acute leukemia: 3 years' experience of pandemic. SHILAP Revista de lepidopterología. 18(4). 45–52. 1 indexed citations
5.
Толстых, Т. Н., et al.. (2024). Chronic lymphocytic leukemia in combination with COVID-19: clinical features and unfavorable prognosis factors. SHILAP Revista de lepidopterología. 18(4). 64–73. 1 indexed citations
6.
Толстых, Т. Н., et al.. (2022). Chemotherapy of hematological malignancies in patients with COVID-19. SHILAP Revista de lepidopterología. 17(2). 107–120.
7.
Семочкин, С. В., et al.. (2021). Management of immune thrombocytopenia during COVID-19 pandemic. 66(1). 20–36.
8.
Семочкин, С. В., et al.. (2019). N-Terminal Fragment of Brain-Type Natriuretic Peptide (NT-proBNP) as a Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma Complicated by Dialysis-Dependent Renal Failure. Bulletin of Experimental Biology and Medicine. 167(2). 267–271. 2 indexed citations
10.
Семочкин, С. В., et al.. (2016). [CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF MYELODYSPLASTIC SYNDROMES IN ADULTS].. PubMed. 108–15. 2 indexed citations
11.
Семочкин, С. В., et al.. (2015). Clinical and epidemiological characteristics of acute myeloid leukemias in adults according to the data of municipal hematology departments in Moscow. Terapevticheskii arkhiv. 87(7). 26–26. 3 indexed citations
12.
Толстых, Т. Н., et al.. (2014). [Experience with high-dose chemotherapy in patients with testicular diffuse large B-cell lymphoma].. PubMed. 86(7). 59–67. 1 indexed citations
13.
Толстых, Т. Н.. (2000). Carboxyl methylation regulates phosphoprotein phosphatase 2A by controlling the association of regulatory B subunits. The EMBO Journal. 19(21). 5682–5691. 206 indexed citations
14.
Lee, Juneyoung, Pei‐Jer Chen, Т. Н. Толстых, & Jeffry B. Stock. (1996). A specific protein carboxyl methylesterase that demethylates phosphoprotein phosphatase 2A in bovine brain.. Proceedings of the National Academy of Sciences. 93(12). 6043–6047. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026